• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    2/12/24 4:01:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAN alert in real time by email
    SC 13G/A 1 elana6_21224.htm PRIMECAP MANAGEMENT CO/CA/ elana6_21224.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 6)*
    Elanco Animal Health Inc
    (Name of Issuer)
    COM
    (Title of Class of Securities)
    28414H103
    (CUSIP Number)
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 28414H103
           
    1
    NAME OF REPORTING PERSON
    PRIMECAP Management Company
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    95-3868081
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    47,570,754
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    50,600,324
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    50,600,324
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    10.27%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: 28414H103
    ITEM 1(a). NAME OF ISSUER:
    Elanco Animal Health Inc
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    2500 Innovation Way, Greenfield, IN 46140
    ITEM 2(a). NAME OF PERSON FILING:
    PRIMECAP Management Company
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105
    ITEM 2(c). CITIZENSHIP:
    U.S.A.
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    COM
    ITEM 2(e). CUSIP NUMBER:
    28414H103
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    50,600,324
    (b) Percent of class:
    10.27%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    47,570,754
    (ii) shared power to vote or to direct the vote:
    0
    (iii) sole power to dispose or direct the disposition of:
    50,600,324
    (iv) shared power to dispose or to direct the disposition of:
    0
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    Not Applicable
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Not Applicable
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    Not Applicable
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    Not Applicable
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 28414H103
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 12 2024
    PRIMECAP Management Company
    By:
    /s/ Julietta Martikyan
    Name:
    Julietta Martikyan
    Title:
    Director of Compliance and Administration
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $ELAN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELAN

    DatePrice TargetRatingAnalyst
    12/9/2024$18.00Buy
    UBS
    12/2/2024$14.00Market Perform
    Leerink Partners
    9/19/2024$17.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    1/5/2024$13.00 → $20.00Hold → Buy
    Stifel
    12/19/2023$17.00Buy
    Jefferies
    12/15/2023$16.00Equal-Weight → Overweight
    Morgan Stanley
    12/7/2023$18.00Outperform
    Exane BNP Paribas
    4/20/2023$14.00Equal Weight → Overweight
    Barclays
    More analyst ratings

    $ELAN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elanco Animal Health Reports First Quarter 2025 Results

      Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported

      5/7/25 6:27:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

      GREENFIELD, Ind., May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the human health application of lotilaner, to funds affiliated with Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash. Monetization of this non-core asset will be used to accelerate debt reduction, positioning Elanco to achieve an expected net leverage ratio of 3.9x to 4.3x adjusted EBITDA by the end of 2025. Elanco will repay portions of its outstanding term loans on a pro-rata basis, which is expected to reduce inte

      5/5/25 6:27:00 AM ET
      $ELAN
      $TARS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day

      National Parvo Awareness Day raises awareness of canine parvovirus (parvo), the often-fatal puppy disease.Elanco's Canine Parvovirus Monoclonal Antibody (CPMA) is the first-and-only USDA conditionally approved treatment for parvo.Puppies treated with CPMA had a 93% survival rate and returned home an average of 1.87 days sooner.1,2Elanco's ParvoTrack, the first-ever national online parvo tracking tool, allows pet owners and veterinarians to self-report outbreaks in real time, further highlighting the need for CPMA across the country and reinforcing Elanco's commitment to increasing the availability of CPMA.Texas, Arizona, Georgia, Florida, Illinois, Indiana and New York have some of the highe

      4/22/25 8:27:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Elanco Animal Health with a new price target

      UBS initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $18.00

      12/9/24 7:40:18 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Elanco Animal Health with a new price target

      Leerink Partners initiated coverage of Elanco Animal Health with a rating of Market Perform and set a new price target of $14.00

      12/2/24 6:55:44 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Elanco Animal Health from Overweight to Equal-Weight and set a new price target of $15.00 from $17.00 previously

      9/19/24 7:41:39 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Elanco Animal Health Incorporated

      10-Q - Elanco Animal Health Inc (0001739104) (Filer)

      5/7/25 9:05:18 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Elanco Animal Health Inc (0001739104) (Filer)

      5/7/25 6:30:46 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Elanco Animal Health Incorporated

      DEFA14A - Elanco Animal Health Inc (0001739104) (Filer)

      3/27/25 12:30:40 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Leadership Updates

    Live Leadership Updates

    See more
    • Elanco Strengthens Board of Directors with Addition of Stacey Ma

      Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen

      11/12/24 8:33:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors

      New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members. Ms. Turner brings significant global experience in both the animal health and broader healthcare industries. She has held senior leadership positions at IDEXX Labora

      4/1/24 6:30:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Appoints Shiv O'Neill as General Counsel and Corporate Secretary

      GREENFIELD, Ind., March 4, 2024 /PRNewswire/ -- Elanco Animal Health (NYSE:ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary. O'Neill will be responsible for the global strategy and operations of the Company's legal team, ethics & compliance organization and ESG efforts. "Shiv's ability to deliver strategic value to Elanco in the short term serving as our interim general counsel combined with her robust experience made it clear that she was the right person for this role," said Jeff Simmons,

      3/4/24 8:33:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Elanco Animal Health Incorporated

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      7/8/24 4:32:39 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      2/13/24 2:08:55 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      2/12/24 4:01:30 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Modi Rajeev A.

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      5/6/25 4:04:57 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      5/6/25 4:04:28 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      4/22/25 5:21:32 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Financials

    Live finance-specific insights

    See more
    • Elanco Animal Health Reports First Quarter 2025 Results

      Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported

      5/7/25 6:27:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Confirms Date and Conference Call for First Quarter 2025 Financial Results Announcement

      GREENFIELD, Ind., April 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2025 financial results on Wednesday, May 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/defau

      4/10/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2024 Financial Results Announcement

      GREENFIELD, Ind., Feb. 4, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-pr

      2/4/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kurzius Lawrence Erik bought $211,000 worth of shares (20,000 units at $10.55), increasing direct ownership by 22% to 111,459 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/11/25 5:13:30 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hoover R David bought $272,558 worth of shares (25,000 units at $10.90) (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/7/25 4:21:21 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Harrington Michael J bought $51,974 worth of shares (3,500 units at $14.85), increasing direct ownership by 5% to 81,094 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      8/26/24 5:05:35 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care